Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma

Ceritinib is a new anaplastic lymphoma kinase (ALK) inhibitor that has shown greater potency in patients with advanced ALK-rearranged non-small cell lung cancer, including those who had disease progression in crizotinib treatment. Here we reported, after several months of ceritinib treatment, two pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Juanyan, Guan, Hui, Yu, Min, Zhou, Ping, Han, Yao, Peng, Xingchen, Zhang, Shuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395502/
https://www.ncbi.nlm.nih.gov/pubmed/35727390
http://dx.doi.org/10.1007/s10637-022-01270-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395502/
https://www.ncbi.nlm.nih.gov/pubmed/35727390
http://dx.doi.org/10.1007/s10637-022-01270-2

Ejemplares similares